Skip to content
Certified ManufacturersFor manufacturers

Innova Softgel LLC DBA KD Nutra

Miami, FL, United States

Due-diligence report

Find an accredited testing lab and confirm its scope covers your product and methods.

Innova Softgel LLC DBA KD Nutra is a dietary supplement manufacturer in Miami, FL, United States, certified to NSF/ANSI 455-2 GMP, with 3 manufacturing and packaging facilities on NSF’s public NSF/ANSI 455 listing as of November 19, 2026. Listed dosage forms: softgels.

Facilities listed
4
Last checked

Dosage forms

As listed in the product categories of this company’s NSF/ANSI 455-2 certified facilities.

Certified facilities

Manufacturing (2)

  • 14193 Southwest 119th Avenue, Miami, FL 33186, United States

    • Encapsulation
    • Mixing
    • Packaging/Labeling Operation
    • Packaging/Labeling Operation - Bulk Packaging
    • Packaging/Labeling Operation - Dispensing
    • Quality Unit Operations
    • Warehousing
  • 14201 Southwest 119th Avenue, Miami, FL 33186, United States

    Facility operated as: KD Nutra Packaging Building

    • Packaging/Labeling Operation
    • Packaging/Labeling Operation - Primary Packaging
    • Packaging/Labeling Operation - Secondary Packaging

Packaging (1)

  • 14201 Southwest 119th Avenue, Miami, FL 33186, United States

    Facility operated as: KD Nutra Packaging Building

    • Packaging/Labeling Operation
    • Packaging/Labeling Operation - Primary Packaging
    • Packaging/Labeling Operation - Secondary Packaging

Distribution (1)

  • 14235 Southwest 119th Avenue, Miami, FL 33186, United States

    Facility operated as: KD Nutra Finished Goods Warehouse

    • Warehousing

How Innova Softgel LLC DBA KD Nutra compares

Among the 769 manufacturers we list, as of our last check.

FDA recall records

No food or dietary supplement recall found under the name Innova Softgel LLC DBA KD Nutra in FDA’s enforcement reports, as of .

We match FDA records by company name only. A recall listed under a different name won’t appear here, and a different company with the same name could. FDA’s food enforcement records start in June 2012. How we check

FDA inspections

FDA lists 6 food or dietary supplement inspections at facilities matching Innova Softgel LLC DBA KD Nutra, from 2010 to 2026, as of . 2 found no objectionable conditions and 4 found conditions the firm was left to correct.

  • No action indicated · No objectionable conditions found

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    FEI 3001596572

  • No action indicated · No objectionable conditions found

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    FEI 3001596572

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    12 citations posted:

    • Equipment - design - no contamination (21 CFR 111.27(a)(2))
    • Quality control - reserve samples (21 CFR 111.105(g))
    • Quality control operations - reprocessing (21 CFR 111.123(a)(5))
    • Examination, testing; appropriate (21 CFR 111.320(a))
    See all 12 citations
    • Equipment - design - no contamination (21 CFR 111.27(a)(2))

      You used equipment or utensils that were not of appropriate design and construction so that the use resulted in contamination of components or dietary supplements.

    • Quality control - reserve samples (21 CFR 111.105(g))

      Your quality control personnel did not ensure that required reserve samples were collected and held.

    • Quality control operations - reprocessing (21 CFR 111.123(a)(5))

      Your quality control operations did not include approving or rejecting reprocessing.

    • Examination, testing; appropriate (21 CFR 111.320(a))

      You did not verify that the laboratory examination and testing methodologies are appropriate for their intended use.

    • Conditions, controls -protect; microorganisms, contamination (21 CFR 111.365(a))

      You did not perform manufacturing operations under conditions and controls that protect against the potential for growth of microorganisms and the potential for contamination.

    • Metal, foreign material (21 CFR 111.365(i))

      You did not use effective measures to protect against the inclusion of metal or other foreign material in dietary supplements.

    • Procedures not in writing, fully followed (21 CFR 211.22(d))

      The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

    • Equipment Design, Size and Location (21 CFR 211.63)

      Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

    • Written procedures fail to include (21 CFR 211.67(b))

      Written procedures for cleaning and maintenance fail to include maintenance and cleaning schedules, description in sufficient detail of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance and instructions for protection of clean equipment from contamination prior to use.

    • Written procedures not established/followed (21 CFR 211.67(b))

      Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

    • Microbiological testing (21 CFR 211.165(b))

      Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

    • Investigations of discrepancies, failures (21 CFR 211.192)

      There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

    FEI 3001596572

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    2 citations posted:

    • Records - document; results (21 CFR 111.325(b)(2)(ii))
    • Written procedures - product complaint (21 CFR 111.553)
    Full citation text
    • Records - document; results (21 CFR 111.325(b)(2)(ii))

      The documentation for laboratory tests and examinations did not include the results of the testing and examination.

    • Written procedures - product complaint (21 CFR 111.553)

      You did not establish and follow written procedures for the requirements to review and investigate a product complaint.

    FEI 3001596572

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    17 citations posted:

    • Procedures - equipment - cleaning, sanitizing (21 CFR 111.25(c))
    • Quality control - batch, product specifications (21 CFR 111.123(b)(2))
    • Written procedures - components (21 CFR 111.153)
    • Manufacturing operations - design (21 CFR 111.355)
    See all 17 citations
    • Procedures - equipment - cleaning, sanitizing (21 CFR 111.25(c))

      You did not follow written procedures for maintaining, cleaning, and sanitizing, equipment, utensils, and any other contact surfaces that are used to manufacture, package, label, or hold components or dietary supplements.

    • Quality control - batch, product specifications (21 CFR 111.123(b)(2))

      Your quality control personnel approved and released for distribution a batch of dietary supplement that did not meet established product specifications.

    • Written procedures - components (21 CFR 111.153)

      You did not establish written procedures for the requirements for components of dietary supplements.

    • Manufacturing operations - design (21 CFR 111.355)

      You did not design or select manufacturing processes that ensure that product specifications are consistently met.

    • Written procedures - holding (21 CFR 111.453)

      You did not follow written procedures for holding and distributing operations.

    • Written procedures - product complaint (21 CFR 111.553)

      You did not follow written procedures for the requirements to review and investigate a product complaint.

    • Inadequate number of personnel (21 CFR 211.25(c))

      The number of qualified personnel is inadequate to supervise the manufacture, processing, packing, and holding of each drug product.

    • Written procedures not established/followed (21 CFR 211.67(b))

      Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

    • Written Procedures Not Followed (21 CFR 211.80(a))

      Written procedures are not followed for the receipt, identification, sampling, approval, and rejection of components.

    • Absence of Written Procedures (21 CFR 211.100(a))

      There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

    • Weighing/measuring/subdividing supervision (21 CFR 211.101(c))

      Component weighing and measuring operations are not adequately supervised.

    • Items to cover on annual reviews (21 CFR 211.180(e)(2))

      Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product.

    • Investigations of discrepancies, failures (21 CFR 211.192)

      There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

    • Written record of investigation incomplete (21 CFR 211.192)

      Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.

    • Adverse Drug Experience (21 CFR 211.198(a))

      Complaint procedures are deficient in that they do not include provisions that allow for the review to determine if the complaints represent serious and unexpected adverse drug experiences which are required to be reported to FDA.

    • Procedures to be written and followed (21 CFR 211.198(a))

      Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.

    • Returned drug procedures in writing and followed (21 CFR 211.204)

      Procedures describing the holding of returned drug products are not followed.

    FEI 3001596572

Show all 6 inspections
  • No action indicated · No objectionable conditions found

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    FEI 3001596572

  • No action indicated · No objectionable conditions found

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    FEI 3001596572

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    12 citations posted:

    • Equipment - design - no contamination (21 CFR 111.27(a)(2))
    • Quality control - reserve samples (21 CFR 111.105(g))
    • Quality control operations - reprocessing (21 CFR 111.123(a)(5))
    • Examination, testing; appropriate (21 CFR 111.320(a))
    See all 12 citations
    • Equipment - design - no contamination (21 CFR 111.27(a)(2))

      You used equipment or utensils that were not of appropriate design and construction so that the use resulted in contamination of components or dietary supplements.

    • Quality control - reserve samples (21 CFR 111.105(g))

      Your quality control personnel did not ensure that required reserve samples were collected and held.

    • Quality control operations - reprocessing (21 CFR 111.123(a)(5))

      Your quality control operations did not include approving or rejecting reprocessing.

    • Examination, testing; appropriate (21 CFR 111.320(a))

      You did not verify that the laboratory examination and testing methodologies are appropriate for their intended use.

    • Conditions, controls -protect; microorganisms, contamination (21 CFR 111.365(a))

      You did not perform manufacturing operations under conditions and controls that protect against the potential for growth of microorganisms and the potential for contamination.

    • Metal, foreign material (21 CFR 111.365(i))

      You did not use effective measures to protect against the inclusion of metal or other foreign material in dietary supplements.

    • Procedures not in writing, fully followed (21 CFR 211.22(d))

      The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

    • Equipment Design, Size and Location (21 CFR 211.63)

      Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

    • Written procedures fail to include (21 CFR 211.67(b))

      Written procedures for cleaning and maintenance fail to include maintenance and cleaning schedules, description in sufficient detail of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance and instructions for protection of clean equipment from contamination prior to use.

    • Written procedures not established/followed (21 CFR 211.67(b))

      Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

    • Microbiological testing (21 CFR 211.165(b))

      Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

    • Investigations of discrepancies, failures (21 CFR 211.192)

      There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

    FEI 3001596572

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    2 citations posted:

    • Records - document; results (21 CFR 111.325(b)(2)(ii))
    • Written procedures - product complaint (21 CFR 111.553)
    Full citation text
    • Records - document; results (21 CFR 111.325(b)(2)(ii))

      The documentation for laboratory tests and examinations did not include the results of the testing and examination.

    • Written procedures - product complaint (21 CFR 111.553)

      You did not establish and follow written procedures for the requirements to review and investigate a product complaint.

    FEI 3001596572

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    17 citations posted:

    • Procedures - equipment - cleaning, sanitizing (21 CFR 111.25(c))
    • Quality control - batch, product specifications (21 CFR 111.123(b)(2))
    • Written procedures - components (21 CFR 111.153)
    • Manufacturing operations - design (21 CFR 111.355)
    See all 17 citations
    • Procedures - equipment - cleaning, sanitizing (21 CFR 111.25(c))

      You did not follow written procedures for maintaining, cleaning, and sanitizing, equipment, utensils, and any other contact surfaces that are used to manufacture, package, label, or hold components or dietary supplements.

    • Quality control - batch, product specifications (21 CFR 111.123(b)(2))

      Your quality control personnel approved and released for distribution a batch of dietary supplement that did not meet established product specifications.

    • Written procedures - components (21 CFR 111.153)

      You did not establish written procedures for the requirements for components of dietary supplements.

    • Manufacturing operations - design (21 CFR 111.355)

      You did not design or select manufacturing processes that ensure that product specifications are consistently met.

    • Written procedures - holding (21 CFR 111.453)

      You did not follow written procedures for holding and distributing operations.

    • Written procedures - product complaint (21 CFR 111.553)

      You did not follow written procedures for the requirements to review and investigate a product complaint.

    • Inadequate number of personnel (21 CFR 211.25(c))

      The number of qualified personnel is inadequate to supervise the manufacture, processing, packing, and holding of each drug product.

    • Written procedures not established/followed (21 CFR 211.67(b))

      Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

    • Written Procedures Not Followed (21 CFR 211.80(a))

      Written procedures are not followed for the receipt, identification, sampling, approval, and rejection of components.

    • Absence of Written Procedures (21 CFR 211.100(a))

      There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

    • Weighing/measuring/subdividing supervision (21 CFR 211.101(c))

      Component weighing and measuring operations are not adequately supervised.

    • Items to cover on annual reviews (21 CFR 211.180(e)(2))

      Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product.

    • Investigations of discrepancies, failures (21 CFR 211.192)

      There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

    • Written record of investigation incomplete (21 CFR 211.192)

      Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.

    • Adverse Drug Experience (21 CFR 211.198(a))

      Complaint procedures are deficient in that they do not include provisions that allow for the review to determine if the complaints represent serious and unexpected adverse drug experiences which are required to be reported to FDA.

    • Procedures to be written and followed (21 CFR 211.198(a))

      Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.

    • Returned drug procedures in writing and followed (21 CFR 211.204)

      Procedures describing the holding of returned drug products are not followed.

    FEI 3001596572

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Miami, Florida

    Listed by FDA as Innova SoftGel LLC

    2 citations posted:

    • Importer verification (21 CFR 123.12(a)(2))
    • Items to cover on annual reviews (21 CFR 211.180(e)(2))
    Full citation text
    • Importer verification (21 CFR 123.12(a)(2))

      You do not have or have not implemented written verification procedures and an affirmative step for ensuring that fishery products you import are processed in compliance with the Seafood HACCP regulation.

    • Items to cover on annual reviews (21 CFR 211.180(e)(2))

      Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product.

    FEI 3001596572

We match FDA inspections to companies by facility ZIP code (or city outside the US) and company name, so an inspection filed under a different name won’t appear here. FDA publishes final classifications only, and holds some back while enforcement is pending. Posted citations may differ from FDA’s final findings. FDA Data Dashboard · How we check

What we checked, and what we didn’t

Confirmed from NSF’s public listing

Last checked

  • NSF/ANSI 455-2 GMP certification
  • 4 facility addresses
  • Dosage forms in the certified scope
  • Operations listed for each facility

Not verified by us

  • Minimum order quantity (MOQ): the smallest order they accept
  • Lead times and current capacity
  • Prices
  • Other certifications, like organic, kosher, halal or NSF Certified for Sport
  • Whether they’re taking new clients
  • Conditions inside the facility. We don’t visit or audit facilities.

Ask about these in your quote request. How we verify

Other softgel manufacturers in the United States

  1. NSF lists 4 softgel facilities, including one in Tempe, AZ

    Tempe, AZ, United States21stcenturyvitamins.com

    • Capsules
    • Gummies
    • Softgels
    • Tablets
    Operations:
    • Kitting
    • Coating
    • Tablet compression
    • Encapsulation
    NSF/ANSI 455-2checked Nov 19, 2026
  2. NSF lists a softgel facility in Garden Grove, CA

    Garden Grove, CA, United Statespackaging.com

    • Capsules
    • Gummies
    • Powders
    • Softgels
    • Tablets
    NSF/ANSI 455-2checked Nov 19, 2026
  3. NSF lists a softgel facility in Ada, MI

    Ada, MI, United Statesamway.com

    • Capsules
    • Powders
    • Softgels
    • Tablets
    Operations:
    • Kitting
    • Coating
    • Tablet compression
    • Encapsulation
    • +1 more
    NSF/ANSI 455-2checked Nov 19, 2026
  4. NSF lists a softgel facility in Miami, FL

    Miami, FL, United Statesalfavitamins.com

    • Capsules
    • Gummies
    • Liquids
    • Softgels
    • Tablets
    Operations:
    • Pasteurization
    • Coating
    • Liquid formulation
    • Tablet compression
    • +1 more
    NSF/ANSI 455-2checked Nov 19, 2026
  5. NSF lists a softgel facility in Springfield, OH

    Springfield, OH, United Statesallinnutritionals.com

    • Capsules
    • Liquids
    • Powders
    • Softgels
    Operations:
    • Liquid formulation
    • Encapsulation
    • Dry formulation
    NSF/ANSI 455-2checked Nov 19, 2026
  6. NSF lists a softgel facility in Dallas, TX

    Dallas, TX, United Statesforeverliving.com

    • Gummies
    • Liquids
    • Powders
    • Softgels
    • Tablets
    Operations:
    • Kitting
    • Coating
    • Liquid formulation
    • Tablet compression
    • +1 more
    NSF/ANSI 455-2checked Nov 19, 2026